How BioMarin Beat Expectations in Q3

2020 is looking like a year to forget for BioMarin Pharmaceutical (NASDAQ: BMRN). The decision by the Food and Drug Administration (FDA) to not approve Roctavian (valoctocogene roxaparvovec) in treating severe hemophilia A rocked the company and its share price. 

BioMarin had an opportunity to give investors some good news when the company announced its third-quarter results after the market closed on Thursday. Here are the highlights from BioMarin's Q3 update.

Image source: Getty Images.

Continue reading

Source Fool.com